Actilyse

PreclinicalSmall molecule

Boehringer Ingelheim

Actilyse is one of 86 small molecule programs targeting Stroke. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

Cerebral InfarctionActive, not recruiting

Ischemic StrokeActive, not recruiting

StrokePreclinical

Active, not recruiting

Cerebral InfarctionPreclinical

Active, not recruiting

Ischemic StrokePreclinical

Active, not recruiting

Competition

Competitive Landscape

147 competitors in Stroke

#DrugCompanyPhaseTrials

Zometa

Pfizer

Preclinical

1 2

Savella

AbbVie

Preclinical

1 3

Proamatine

Repatha

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Zantac 150

CChattem

Preclinical

1 7

Alka-Seltzer

AAbbott

Preclinical

1 8

Haldol

DDePuy Orthopaedics

Preclinical

1 9

Inderal

Mylan Pharmaceuticals Inc

Coumadin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Stroke2 trials

Intracranial Collaterals in Acute Stroke and Clinical Outcome

Completed·—··NCT03311386·40 enrolled

New Acute Treatment for Stroke - The Effect of Remote PERconditioning

Completed·—·Phase 3·NCT00975962·120 enrolled

Cerebral Infarction1 trial

Which Factors Influence the Duration and the Success of Mechanical Thrombectomy During the Acute Phase of Cerebral Infarction?

Completed·—··NCT03451903·106 enrolled

Myocardial Infarction1 trial

Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction

Completed·AAO GENERIUM·Phase 3·NCT07146360·180 enrolled

Pulmonary Embolism1 trial

Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism

Completed·UUniversity Hospital Ostrava·Phase 4·NCT02132689·100 enrolled

Ischemic stroke1 trial

Anxiety and Depression Disorder in Patient Treated With rTPA for Mangment of Acute Ischemic Stroke

Unknown status·—··NCT04484558·40 enrolled

2 more indications

Efficacy and Safety1 trial

Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device Occlusion

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01958164·16 enrolled

Unspecified1 trial

Protocol for Post Marketing Surveillance of Actilyse Vial

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02229799·265 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Actilyse. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Actilyse compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Actilyse. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Boehringer Ingelheim

Actilyse

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Stroke2 trials

Cerebral Infarction1 trial

Myocardial Infarction1 trial

Pulmonary Embolism1 trial

Ischemic stroke1 trial

Efficacy and Safety1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News